Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Japan's Astellas to buy Audentes for $3 billion in high-priced gene therapy bet

12/03/2019 | 03:14am EDT
Astellas Pharma's logo is pictured at its headquarters in Tokyo

Japan's Astellas Pharma Inc is buying U.S. drugmaker Audentes Therapeutics Inc for about $3 billion in cash, in a high-priced push to make genetic medicines a key area of growth.

Gene therapies are one of the hottest areas of drug research and Astellas, Japan's second-largest drugmaker by sales, is offering $60 per share for San Francisco-based Audentes, a 110% premium to its closing price on Monday.

Citi analyst Hidemaru Yamaguchi said that while the deal looked expensive, it was a positive move for Astellas as Audentes had "cutting-edge gene therapy modalities".

"We thought it was only a matter of time before Astellas entered the gene therapy market," he wrote in a note for clients, adding it had already licensed development rights for a domestic gene therapy in Amyotrophic lateral sclerosis (ALS).

Gene therapies aim to cure diseases by replacing the missing or mutated version of a gene found in a patient's cells with healthy copies. With the potential to cure devastating illnesses in a single dose, drugmakers say they justify prices well above $1 million per patient.

"As a result of this acquisition, Astellas will obtain not only Audentes programs but also it's proprietary manufacturing knowhow in gene therapy," Astellas CFO Naoki Okamura told a briefing in Tokyo. "Internal manufacturing capability is a great strength for companies with multiple programs under development."

Genetic drugs will become a fifth primary focus for Astellas, Okamura said, joining existing business lines in regenerative, immuno-oncology, immunotherapy, and neuro-muscular medicine.

The acquisition marks the second biggest on record for Astellas after its 2010 purchase of OSI Pharmaceuticals Inc for$3.8 billion, according to Refinitiv data. Astellas expects the deal, which is subject to regulatory approval including U.S. antitrust clearance, to close in the first quarter of 2020.

Audentes' investigational drug, AT132, is being developed to treat a rare genetic neuromuscular disorder which results in extreme muscle weakness, respiratory failure and in some cases early death.

Astellas said the companies plan to seek FDA approval for AT312 in mid-2020. The drug has shown promising results in the treatment of X-linked myotubular myopathy (XLMTM) seen mainly in male infants, it said.

Only about 40 boys are born in the United States with the condition each year, so that would yield just $80 million in revenue, said Jefferies analyst Stephen Barker, assuming a maximum price tag for the treatment.

"The $3 billion acquisition price is therefore more likely to be mainly predicated on the firm's technology platform and manufacturing capabilities," Barker wrote in a note.

The deal also marks the latest consolidation in the industry which saw Japan's Takeda Pharmaceutical Co Ltd acquire Britain's Shire for $59 billion.

Shares in Astellas fell 1.1% on Tuesday in Tokyo, underperforming a 0.6% decline in the broader market <.N225>.

The stock's decline was "the natural reaction", said Credit Suisse analyst Fumiyoshi Sakai.

"This is a difficult deal to digest because it deals with gene therapy," Sakai said. "They have to be very square with the investment community about what they're buying."

Morgan Stanley & Co LLC, is Astellas' financial adviser while Covington & Burling LLP is the company's legal counsel.

Centerview Partners LLC is acting as financial adviser to Audentes and Fenwick & West LLP is its legal counsel.

(Reporting by Dania Nadeem in Bengaluru and Rocky Swift in Tokyo; Editing by Anil D'Silva, Edwina Gibbs and Muralikumar Anantharaman)

ę Reuters 2019
Stocks mentioned in the article
ChangeLast1st jan.
ALS LIMITED 1.81% 12.95 End-of-day quote.34.76%
AMP LIMITED 4.89% 0.965 End-of-day quote.-38.14%
ASTELLAS PHARMA INC. -0.67% 1863.5 End-of-day quote.16.91%
EXTREME CO.,LTD. 0.73% 1247 End-of-day quote.7.69%
MORGAN STANLEY 2.73% 103.55 Delayed Quote.47.09%
SQUARE, INC. 2.16% 266.72 Delayed Quote.19.96%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -0.51% 3740 End-of-day quote.-0.40%
08:05aASTELLAS PHARMA INC. : will present 12-week results (S-13) from the pivotal Phase 3 SKYLIG..
09/22Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic..
09/22Astellas to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2Ö Trial in Ora..
09/22ASTELLAS PHARMA : to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2™ ..
09/21ASTELLAS PHARMA : Science-based Exercise at Home with Fit-eNce HomeTM Pilot Sales Begins T..
09/20ASTELLAS PHARMA : ' and Pfizer's XTANDI« (enzalutamide) Reduced Risk of Death by 34% in Me..
09/20ASTELLAS PHARMA : ' and pfizer's xtandi (enzalutamide) reduced risk of death by 34% in men..
09/09ASTELLAS PHARMA : Updates “Contact for Potential Acquisition of ' R&D Programs&rdquo..
09/02ASTELLAS PHARMA : Nitto, and M. Heart Partnering for ECG testing service
09/01Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked My..
More news
Sales 2022 1 325 B 12 009 M 12 009 M
Net income 2022 194 B 1 763 M 1 763 M
Net cash 2022 478 B 4 329 M 4 329 M
P/E ratio 2022 17,6x
Yield 2022 2,68%
Capitalization 3 453 B 31 344 M 31 300 M
EV / Sales 2022 2,25x
EV / Sales 2023 1,89x
Nbr of Employees 15 455
Free-Float 98,9%
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 863,50 JPY
Average target price 2 451,54 JPY
Spread / Average Target 31,6%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291